Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07216404 · ClinicalTrials.gov registry record · Phase 2
Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer
A Phase 2 study of Lung Non-Small Cell Carcinoma and Unipolar Depression, sponsored by Alan Davis.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT07216404 is a Phase 2 study of Lung Non-Small Cell Carcinoma and Unipolar Depression that is actively recruiting participants, run by Alan Davis. The registered enrollment target is 10 participants, below the 160-participant average among 47 other Lung Non-Small Cell Carcinoma trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07216404, a Phase 2 study of Lung Non-Small Cell Carcinoma and Unipolar Depression, is actively recruiting participants, sponsored by Alan Davis.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial tests the safety and side effects of psilocybin in combination with therapy for the treatment of major depressive disorder in patients with non-small cell lung cancer. A cancer diagnosis is life-changing, resulting in significant levels of psychological symptoms, including a combination of depression, anxiety, stress, including feelings of existential distress (i.e., loss of meaning, demoralization, despair). Among all cancer patients, those diagnosed with lung cancer have the highest prevalence of mood disorders, such as depression (up to 40%) leading to profound deterioration in quality of life, prolonged hospital stays, poorer treatment adherence, decreased survival rates, and high rates of suicide (5- and 3-times higher than the general population and other cancer patients, respectively). Psilocybin is substance being studied in the treatment of anxiety or depression in patients with advanced cancer. It is taken from the mushroom Psilocybe mexicana. Psilocybin acts on the brain to cause hallucinations (sights, sounds, smells, tastes, or touches that a person believes to be real but are not real). Psilocybin in combination with therapy may be safe and effective in treating major depressive disorder in patients with non-small cell lung cancer.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Survey Administration
- DRUG Psilocybin
- OTHER Interview
- OTHER Counseling
Study Locations (1)
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2026-03-01 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07216404
The ClinicalTrials.gov registry entry for NCT07216404 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 160-participant average among 47 other Lung Non-Small Cell Carcinoma trials with a reported enrollment target (94% lower). The listed sponsor is Alan Davis, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lung Non-Small Cell Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT07216404 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT07216404 about?
NCT07216404 is a clinical study titled "Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer". This phase II trial tests the safety and side effects of psilocybin in combination with therapy for the treatment of major depressive disorder in patients with non-small cell lung cancer. A cancer diagnosis is life-changing, resulting in significant levels of psychological symptoms, including a comb...
What is the current status of trial NCT07216404?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2026-03-01. Estimated completion is 2026-12-31.
What conditions does trial NCT07216404 study?
This clinical trial studies the following conditions: Lung Non-Small Cell Carcinoma, Unipolar Depression.
What interventions are being tested in trial NCT07216404?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Survey Administration (OTHER), Psilocybin (DRUG), Interview (OTHER), Counseling (OTHER).
Who is sponsoring clinical trial NCT07216404?
This trial is sponsored by Alan Davis, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07216404 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Non-Small Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer
RECRUITING · Phase 2
-
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
RECRUITING · Phase 2
-
Grid Radiation Therapy for the Treatment of Stage IV Non-Small Cell Lung Cancer
RECRUITING · Phase 2
-
Phase II Trial of Lung Chemoemobolization
RECRUITING · Phase 2
-
Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma
RECRUITING · Phase 2
-
Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.